Atara Biotherapeutics (ATRA) Other Non-Current Liabilities (2013 - 2026)

Atara Biotherapeutics' Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• Quarterly Other Non-Current Liabilities fell 41.51% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 41.51% YoY) and the FY2025 annual result came in at $1.8 million, down 45.09% from the prior year.
• Other Non-Current Liabilities was $1.8 million for Q1 2026 at Atara Biotherapeutics, up from $1.8 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $40.8 million in Q2 2025 and bottomed at $616000.0 in Q1 2022.
• A 5-year average of $6.0 million and a median of $4.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 69.6% — and 2025, when it surged 878.95%.
• Atara Biotherapeutics' Other Non-Current Liabilities stood at $5.6 million in 2022, then dropped by 16.77% to $4.6 million in 2023, then slipped by 29.41% to $3.3 million in 2024, then plunged by 45.09% to $1.8 million in 2025, then grew by 1.89% to $1.8 million in 2026.
• Business Quant data shows ATRA's Other Non-Current Liabilities at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.